Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1966 1
1967 5
1968 8
1969 3
1970 5
1971 5
1972 8
1973 7
1974 3
1975 8
1976 6
1977 3
1978 3
1979 3
1980 2
1982 1
1983 2
1984 2
1986 3
1987 1
1989 6
1990 1
1991 1
1992 1
1993 2
1995 2
1996 2
1997 14
1998 6
1999 5
2000 3
2001 6
2002 7
2003 8
2004 9
2005 11
2006 28
2007 31
2008 24
2009 30
2010 23
2011 34
2012 26
2013 35
2014 19
2015 16
2016 13
2017 12
2018 19
2019 9
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

444 results
Results by year
Filters applied: . Clear all
Page 1
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Lasko LM, Jakob CG, Edalji RP, Qiu W, Montgomery D, Digiammarino EL, Hansen TM, Risi RM, Frey R, Manaves V, Shaw B, Algire M, Hessler P, Lam LT, Uziel T, Faivre E, Ferguson D, Buchanan FG, Martin RL, Torrent M, Chiang GG, Karukurichi K, Langston JW, Weinert BT, Choudhary C, de Vries P, Van Drie JH, McElligott D, Kesicki E, Marmorstein R, Sun C, Cole PA, Rosenberg SH, Michaelides MR, Lai A, Bromberg KD. Lasko LM, et al. Nature. 2017 Oct 5;550(7674):128-132. doi: 10.1038/nature24028. Epub 2017 Sep 27. Nature. 2017. PMID: 28953875 Free PMC article.
Structural basis for DNMT3A-mediated de novo DNA methylation.
Zhang ZM, Lu R, Wang P, Yu Y, Chen D, Gao L, Liu S, Ji D, Rothbart SB, Wang Y, Wang GG, Song J. Zhang ZM, et al. Nature. 2018 Feb 15;554(7692):387-391. doi: 10.1038/nature25477. Epub 2018 Feb 7. Nature. 2018. PMID: 29414941 Free PMC article.
Myeloproliferative neoplasms: from origins to outcomes.
Nangalia J, Green AR. Nangalia J, et al. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):470-479. doi: 10.1182/asheducation-2017.1.470. Hematology Am Soc Hematol Educ Program. 2017. PMID: 29222295 Free PMC article. Review.
JAK2 inhibitors for myeloproliferative neoplasms: what is next?
Bose P, Verstovsek S. Bose P, et al. Blood. 2017 Jul 13;130(2):115-125. doi: 10.1182/blood-2017-04-742288. Epub 2017 May 12. Blood. 2017. PMID: 28500170 Free PMC article. Review.
Treating early-stage myelofibrosis.
Palandri F, Sabattini E, Maffioli M. Palandri F, et al. Ann Hematol. 2019 Feb;98(2):241-253. doi: 10.1007/s00277-018-3526-z. Epub 2018 Oct 20. Ann Hematol. 2019. PMID: 30343328 Review.
Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.
Flinn IW, O'Brien S, Kahl B, Patel M, Oki Y, Foss FF, Porcu P, Jones J, Burger JA, Jain N, Kelly VM, Allen K, Douglas M, Sweeney J, Kelly P, Horwitz S. Flinn IW, et al. Blood. 2018 Feb 22;131(8):877-887. doi: 10.1182/blood-2017-05-786566. Epub 2017 Nov 30. Blood. 2018. PMID: 29191916 Free PMC article. Clinical Trial.
NADPH oxidases and cancer.
Roy K, Wu Y, Meitzler JL, Juhasz A, Liu H, Jiang G, Lu J, Antony S, Doroshow JH. Roy K, et al. Clin Sci (Lond). 2015 Jun;128(12):863-75. doi: 10.1042/CS20140542. Clin Sci (Lond). 2015. PMID: 25818486 Review.
Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation.
Jacquelin S, Straube J, Cooper L, Vu T, Song A, Bywater M, Baxter E, Heidecker M, Wackrow B, Porter A, Ling V, Green J, Austin R, Kazakoff S, Waddell N, Hesson LB, Pimanda JE, Stegelmann F, Bullinger L, Döhner K, Rampal RK, Heckl D, Hill GR, Lane SW. Jacquelin S, et al. Blood. 2018 Dec 27;132(26):2707-2721. doi: 10.1182/blood-2018-04-846220. Epub 2018 Oct 26. Blood. 2018. PMID: 30366920
444 results
Jump to page
Feedback